John Vaughn on Muck Rack

John Vaughn

Yuma
As seen in: Nature, Wiley Online Library, Royal Society of Chemistry, Bajo El Sol, Yuma Sun, Chemistry World, Imperial Valley Press, Tri-County Times
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with John

Contact John, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Evaluation of incidence and outcomes of transformed nodular lymphocyte predominant Hodgkin Lymphoma in the United States: a population-based cohort study

|
By John Vaughn, Malak Munir, Ashley Cobb, Sravani Rimmalapudi, Narendranath Epperla
| Nature Verified
To the Editor, Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is an indolent B-cell lymphoma with a distinct biology and favorable prognosis [1]. However, a subset of patients experience histologic transformation (HT) to diffuse large B-cell lymphoma (DLBCL), an event generally associated with adverse outcomes in other indolent lymphomas [2]. The incidence and clinical implications of HT in NLPHL are incompletely defined.
Open in Who Shared Issue with article?

Trends in Incidence and Survival of Patients With Primary Effusion Lymphoma in the United States: A Population Based Cohort Study

|
By John Vaughn, Malak Munir, Gardenia Taza, Sravani Rimmalapudi
| Wiley Online Library Verified
1 Introduction Primary effusion lymphoma (PEL) is a rare type of B-cell non-Hodgkin lymphoma (NHL) that was first classified by the World Health Organization (WHO) in 2001 [1]. PEL is characterized by malignant effusions in body cavities usually in the absence of extracavitary masses. Symptoms are dependent on the affected cavities and often include B-symptoms. PEL is commonly associated with human immunodeficiency virus (HIV) infection.
Open in Who Shared Issue with article?

Site-specific prognosis and temporal trends in extranodal marginal zone lymphoma patients in the United States - Blood Cancer Journal

|
By John Vaughn
| Nature Verified
To the Editor, Marginal zone lymphoma (MZL) is an indolent B-cell non-Hodgkin lymphoma that accounts for ~7% of all non-Hodgkin lymphomas [1]. MZL is a heterogeneous disease and includes three subtypes, nodal MZL, splenic MZL, and extranodal MZL of mucosa-associated lymphoid tissue (EMZL). The management of EMZL has evolved over time, with the introduction of rituximab, bendamustine, Bruton Tyrosine Kinase Inhibitors (BTKi), and lenalidomide [2,3,4,5].
Open in Who Shared Issue with article?
See all 916 licensed articles (959 Total)
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified